Drugs & Aging

, Volume 27, Issue 5, pp 367–375 | Cite as

Overcoming Gaps in the Management of Chronic Obstructive Pulmonary Disease in Older Patients

New Insights
Review Article

Abstract

Chronic obstructive pulmonary disease (COPD) is a common disorder with a high prevalence among elderly men and women and an increasing mortality rate. Its diagnosis relies on spirometry, with a diagnostic cut-off value of a forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of <0.7. This cut-off level has received some criticism because a ratio decline is part of normal advanced aging. Thus, clinicians must be vigilant in applying appropriate diagnostic criteria when managing elderly patients and may choose to use one or more of the alternative diagnostic values that have been created.

It is important to remember that COPD is a systemic disorder with several extrapulmonary manifestations. Elderly patients with COPD are at an increased risk of cardiovascular events, osteoporosis, fractures, peripheral muscle wasting, depression and anxiety. Management of these patients requires a multidisciplinary approach and should begin with stratification of disease severity and prognostic information for each patient.

Traditionally, FEV1 has been used as a marker of COPD severity. However, indices such as the Modified Medical Research Council (MMRC) Dyspnoea Scale; the updated body mass, airflow, obstruction, dyspnoea and exercise (BODE) index; and the new age, dyspnoea, obstruction (ADO) index have been found to be better predictors of mortality in elderly patients.

In addition to smoking cessation, supplemental oxygen and vaccines, management strategies such as patient education programmes — which have been shown to reduce hospital admissions — should not be overlooked. Pulmonary rehabilitation remains an underutilized treatment modality despite its demonstrated association with improvements in quality of life, reduced dyspnoea and increased exercise capacity. Studies have shown no correlation between age and outcomes in pulmonary rehabilitation, suggesting that age should not be an exclusion criterion. Although bronchodilators and corticosteroids remain the cornerstone of pharmaceutical management of COPD, their efficacy relies on correct medication administration. Inhaler technique should be frequently assessed in the elderly population and the choice of inhaler device needs to be tailored to the patients’ needs, situation and preferences. Assessment and management of extrapulmonary co-morbidities of COPD should also be undertaken. Careful attention to the mental health of elderly patients with COPD is also vital, as they have high rates of depression and anxiety. Furthermore, elderly patients with severe COPD receive inadequate palliative care despite the elevated mortality risk associated with this illness. Early discussion about end-of-life care and advanced care planning is recommended.

References

  1. 1.
    O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease: 2008 update. Can Respir J 2008 Jan–Feb; 15Suppl. A: 1A–8APubMedGoogle Scholar
  2. 2.
    Kaplan A, Hernandez P, O’Donnell DE. Less smoke, more fire: what’s new for you in the latest COPD guidelines? Can Fam Physician 2008; 54: 737–9PubMedGoogle Scholar
  3. 3.
    Statistics Canada. Selected leading causes of death, by sex — Canada [online]. Available from URL: http://www40.statcan.gc.ca/l01/cst01/health36-eng.htm [Accessed 2009 Aug 28]
  4. 4.
    Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 2008; 15: 13–9PubMedGoogle Scholar
  5. 5.
    Swanney MP, Ruppel G, Enright PL. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046–51PubMedCrossRefGoogle Scholar
  6. 6.
    Hardie JA, Buist AS, Vollmer WM, et al. Risk of overdiagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117–22PubMedCrossRefGoogle Scholar
  7. 7.
    Vollmer WM, Gíslason P, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009; 34(3): 588–97PubMedCrossRefGoogle Scholar
  8. 8.
    Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245–57PubMedCrossRefGoogle Scholar
  9. 9.
    Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580–6PubMedCrossRefGoogle Scholar
  10. 10.
    Celli BR, Cote MD, Marin JM. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–12PubMedCrossRefGoogle Scholar
  11. 11.
    Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704–11PubMedCrossRefGoogle Scholar
  12. 12.
    Brooks SM. Task group on surveillance for respiratory hazards in the occupational setting. Surveillance for respiratory hazards. ATS News 1982; 8: 12–6Google Scholar
  13. 13.
    McIvor RA, Todd DC, Cox G. Approach to chronic obstructive pulmonary disease in primary care. Can Fam Physician 2008; 54: 706–11PubMedGoogle Scholar
  14. 14.
    Nishimura K, Izumi T, Tsukino M. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–40PubMedCrossRefGoogle Scholar
  15. 15.
    Gerardi DA, Lovett L, Benoit-Connors ML, et al. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 1996; 9: 431–5PubMedCrossRefGoogle Scholar
  16. 16.
    Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856–61PubMedGoogle Scholar
  17. 17.
    American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–7Google Scholar
  18. 18.
    Schunemann H. From BODE to ADO to outcomes in multi-morbid COPD patients. Lancet 2009; 374(9691): 667–8PubMedCrossRefGoogle Scholar
  19. 19.
    Calverley PM, Anderson JA, Celli BR, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89PubMedCrossRefGoogle Scholar
  20. 20.
    Sidney S, Sorel M, Quesenberry Jr CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–75PubMedCrossRefGoogle Scholar
  21. 21.
    Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099–107PubMedCrossRefGoogle Scholar
  22. 22.
    Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10–4PubMedCrossRefGoogle Scholar
  23. 23.
    Dam TT, Harrison S, Fink HA, et al., for the Osteoporotic Fractures in Men (MrOS) Research Group. Bone mineral densities and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int. Epub 2009 Oct 9Google Scholar
  24. 24.
    Jagoe RT, Englen MP. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. Eur Respir J 2003; 22Suppl. 46: 52S–63SCrossRefGoogle Scholar
  25. 25.
    Schols AM, Mostert R, Soeters PB, et al. Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax 1991; 46: 695–9PubMedCrossRefGoogle Scholar
  26. 26.
    Troosters T, Casaburi R, Gosselink R, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19–38PubMedCrossRefGoogle Scholar
  27. 27.
    Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 629–34PubMedGoogle Scholar
  28. 28.
    Wilson DO, Rogers RM, Wright EC, et al. Body weight in chronic obstructive pulmonary disease: the National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989; 139: 1435–8PubMedGoogle Scholar
  29. 29.
    Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173: 79–83PubMedCrossRefGoogle Scholar
  30. 30.
    Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing 2004; 33(6): 548–55PubMedCrossRefGoogle Scholar
  31. 31.
    Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205–11PubMedCrossRefGoogle Scholar
  32. 32.
    Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134Suppl. 4: 43S–56SPubMedCrossRefGoogle Scholar
  33. 33.
    Solano JP, Gomes B, Higginson IJ, et al. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Sympton Manage 2006; 31(1): 58–69CrossRefGoogle Scholar
  34. 34.
    Cully JA, Graham DP, Stanley MA, et al. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006; 47: 312–9PubMedCrossRefGoogle Scholar
  35. 35.
    Bosley CM, Corden ZM, Rees PJ, et al. Psychological factors associated with use of home nebulizer therapy for COPD. Eur Respir J 1996; 9: 2346–50PubMedCrossRefGoogle Scholar
  36. 36.
    Stapleton RD, Nielsen EL, Engelberg RA, et al. Association of depression and life-sustaining treatment preferences in patients with COPD. Chest 2005 Jan; 127(1): 328–34PubMedCrossRefGoogle Scholar
  37. 37.
    Light RW, Merrill EJ, Despars JA, et al. Prevalence of depression and anxiety in patients with COPD: relationship to functional capacity. Chest 1985; 87(1): 35–8PubMedCrossRefGoogle Scholar
  38. 38.
    Fan VS, Ramsey SD, Giardino ND, et al. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007; 167(21): 2345–53PubMedCrossRefGoogle Scholar
  39. 39.
    Kunik ME, Azzam PN, Souchek J, et al. A practical screening tool for anxiety and depression in patients with chronic breathing disorders. Psychosomatics 2007; 48: 16–21PubMedCrossRefGoogle Scholar
  40. 40.
    Bourbeau J, Julien M, Maltais F, et al. Reduction ofhospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585–91PubMedCrossRefGoogle Scholar
  41. 41.
    Brooks D, Sottana R, Bell B, et al. Characterization of pulmonary rehabilitation programs in Canada in 2005. Can Resp J 2007; 14: 87–92Google Scholar
  42. 42.
    Bendstrup KE, Ingemann JJ, Holm S, et al. Outpatient rehabilitation improves activities of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2801–16PubMedCrossRefGoogle Scholar
  43. 43.
    Troosters T, Gosselink R, Decramer M, et al. Exercise training in COPD: how to distinguish responders from nonresponders. J Cardiopulm Rehabil 2001; 21: 10–7PubMedCrossRefGoogle Scholar
  44. 44.
    Baltzan MA, Kamel H, Alter A, et al. Pulmonary rehabilitation improves functional capacity in patients 80 years of age or older. Can Respir J 2004; 11: 407–13PubMedGoogle Scholar
  45. 45.
    Di Meo F, Pedone C, Lubich S, et al. Age does not hamper the response to pulmonary rehabilitation of COPD patients. Age Ageing 2008; 37: 530–5PubMedCrossRefGoogle Scholar
  46. 46.
    Ferguson GT, Peter MA, Calverley MD, et al. Prevalence and progression of osteoporosis in patients with COPD: results from TORCH. Chest 2009; 136(6): 1456–65PubMedCrossRefGoogle Scholar
  47. 47.
    Remillard AJ. A pharmacoepidemiological evaluation of anticholinergic prescribing patterns in the elderly. Pharmacoepidemiol Drug Saf 1996 May; 5(3): 155–64PubMedCrossRefGoogle Scholar
  48. 48.
    Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3(4): 335–48PubMedCrossRefGoogle Scholar
  49. 49.
    Melani AS. Inhalatory therapy training: a priority challenge for the physicians. Acta Biomed 2007; 78(3): 233–45PubMedGoogle Scholar
  50. 50.
    Dow L, Fowler L, Lamb H. Elderly people’s technique in using dry powder inhalers: new inhaler devices are rarely used by older people in the community [letter]. BMJ 2001; 323: 49–50PubMedCrossRefGoogle Scholar
  51. 51.
    Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med Epub 2009 Dec 1Google Scholar
  52. 52.
    Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988; 17: 275–8PubMedCrossRefGoogle Scholar
  53. 53.
    Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients: time for re-evaluation? Age Ageing 2007; 36: 213–8PubMedCrossRefGoogle Scholar
  54. 54.
    Goodridge DM, Marciniuk DD, Brooks D, et al. End-of-life care for persons with advanced chronic obstructive pulmonary disease: report of a national interdisciplinary consensus meeting. Can Respir J 2009; 16(5): e51–3PubMedGoogle Scholar
  55. 55.
    Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J 2008; 32: 796–803PubMedCrossRefGoogle Scholar
  56. 56.
    Knauft ME, Nielsen EL, Engelberg RA, et al. Barriers and facilitators to communication about end-of-life care for patients with COPD. Chest 2005; 127: 2188–96PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Department of Internal MedicineQueens UniversityKingstonCanada
  2. 2.Firestone Institute for Respiratory Health, St. Joseph’s HealthcareMcMaster University T2127HamiltonCanada

Personalised recommendations